Standard Antidepressant Pharmacotherapy for the Acute Treatment of Mood Disorders

Michael J. Burke, M.D., Ph.D.
Assistant Professor
Department Of Psychiarty
University of Kansas School Of Medicine - Wichita
1010 North Kansas
Wichita, Kansas 67214


Sheldon H. Preskorn, M.D.
Professor and Vice Chairman
Department of Psychiatry
University of Kanasa School of Medicine - Wichita
1010 North Kansas
Wichita, Kansas 67214

President and Director
Psychiatric Research Institute
1100 North St. Francis, Suite 200
Wichita, Kansas 67214


1. Aberg-Wistedt A. Comparison between zimelidine and desipramine in endogenous depression: a crossover study. Acta Psychiatry Scand 1982;66:129-138.

2. Altamura A, Montgomery S, Wernicke J. The evidence for 20 mg a day fluoxetine as the optimal in the treatment of depression. Br J Psychiatry 1988;153(suppl.3):109-112.

3. Baron B, Ogden A, Siegel B, et al. Rapid down regulation of adrenoreceptors by co-administration of desipramine and fluoxetine. Pharmacology 1988;154:125-134.

4. Beasley C, Dornseif B, Pultz J. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1990;52:294-299.

5. Bech, Per. Acute therapy of depression. J Clin Psychiatry 1993;54:18-27.

6. Benfield P, Heel R, Lewis S. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986;32:481-508.

7. Berwish N, Amsterdam J. An overview of investigational antidepressants. Psychosomatics 1989;30:1-17.

8. Bickel ML. Poisoning by tricyclic antidepressants: general and pharmacokinetic considerations. Int J Clin Pharmacol 1975;11:145-176.

9. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993;52:1023-1029.

10. Bresnahan DB, Pandey GN, Janicak PG, et al. MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 1990;51:47-50.

11. Bupp S, Preskorn S. The effect of age on plasma levels of nortriptyline. Ann Clin Psychiatry 1991;3:61-65.

12. Caccia S, Ballabio M, Samanin R, et al. o-m-chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 1981;33:477-478.

13. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a therapeutic window? J Clin Psychiatry 1992;53:272-277.

14. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Eng J Med 1996;335:1010-1015.

15. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-565.

16. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-138.

17. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299.

18. Davidson J, McCleod M, Blum M. Acetylation phenotype, platelet monoamine oxidase inhibition, and effectiveness of phenelzine in depression. Am J Psychiatry 1978;135:467-469.

19. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256-261.

20. Depression Guideline Panel. Depression in Primary Care: Vol. 2. Treatment of major depression. clinical practice guideline, Number 5. Rockville, MD. U.S. Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR No. 93-0551. April, 1993.

21. Dornseif B, Dunlop S, Potrin J, et al. Effect of dose escalation after low dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-79.

22. Dunner D, Dunbar G. Optimal dose regiment for paroxetine. J Clin Psychiatry 1992;53:21-26.

23. Eison A, Eison M, Torrente J, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990;26:311-315.

24. Emrich H, Berger M, Riemann D, et al. Serotonin reuptake inhibition versus norepinephrine reuptake inhibition: a double-blind differential therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatrica 1987;20:60-63.

25. Fawcett J, Marcus R, Anton S, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42.

26. Feighner J, Boyer W. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology 1988;95:S50-S53.

27. Gelenberg A, Schoonover S. The practitioner's guide to psychoactive drugs. Gelenberg, Bassuk, Schoonover, eds. New York: Plenum Publishing Co., 1991;77.

28. Georgotas A, McCue R, Cooper T, et al. Factors effecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989;28:1-9.

29. Glassman A, Preud'homme X. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54:16-22.

30. Golden R, James S, Sherer M. Psychosis associated with bupropion treatment. Am J Psychiatry 1985;142:1459-1462.

31. Golden R, DeVane C, Laizure S, et al. Bupropion in depression: the role of metabolites in clinical outcome. Arch Gen Psychiatry 1985;45:145-149.

32. Goodnick P, Sandoval R. Blood levels and acute response to bupropion. Am J Psychiatry 1992;149:399-400.

33. Goodnick PJ. Pharmacokinetic optimization of therapy with newer antidepressants. Clin Pharmacokinet 1994;27:307-330.

34. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-355.

35. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996;16:273-285.

36. Haykal R, Akiskal H. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450-455.

37. Hoer D, Clarke D, Fozard J, et al. VII International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.

38. Janicak P, Davis J, Preskorn S, Ayd F. Principles and practice of psychopharmacotherapy. Baltimore: Williams and Wilkens, 1993; 223-240.

39. Kahn R, Asiris G, Wetzler S, et al. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 1988;96:360-364.

40. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.

41. Katz M, Koslow S, Maas J, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987;17:297-309.

42. Katzelnick DJ, Kobak KA, Jefferson JW, et al. Prescribing patterns of antidepressant medications for depression in a health care organization, 1993. Dean Foundation for Health Research and Education. Poster session, NCDEU, 1995.

43. Kelly M, Perry P, Holstad S, et al. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989;11:165-170.

44. Kerr T, McClelland H, Stephens D, et al. Trazodone: a comparative clinical and predictive study. Acta Psychiatr Scand 1984;70: 573-577.

45. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52(suppl):28-34.

46. Lemberger L, Bergstrom R, Wolen R, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-19.

47. Liebowitz M, Quitkin F, Stewart J, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137.

48. Marsden CA, Tyrer P, Casey P, et al. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. Psychopharmacology 1987;1:244-250.

49. McElhatton PR, Garbis HM, Elefant E, et al. The outcome off pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of teratology information services. Reprod Toxicol 1996;10:285-294.

50. McGrath P, Stewart J, Harrison W, et al. Predictive value of symptoms of atypical depression for differential drug outcome. J Clin Psychopharmacol 1992;12:197-202.

51. Meredith C, Feighner J. The use of bupropion in hospitalized depressed patients. J Clin Psychiatry 1983;44:85-87.

52. Mitchell PB. Novel French antidepressants not available in the United States. Psychopharmacol Bull 1995;31:509-518.

53. Nulman I, Rovet J, Stewart D, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Eng J Med 1997;336:258-262.

54. Nystrom C, Ross S, Hallstrom T, et al. Comparison between serotonin and norepinephrine reuptake blocker in the treatment of depressed outpatients: a crossover study. Acta Psychiatr Scand 1987;75 377-382.

55. Othmer S, Othmer E, Preskorn S, et al. Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study. J Clin Psychiatry 1988;49:310-312.

56. Parker G, Roy K, Hadzi-Pavlovic D, et al. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992;24:17-24.

57. Paykel E, Hollyman J, Freeling P, et al. Predictor for therapeutic benefit from amitriptyline in mild depression: A general practice placebo controlled trial. J Affect Disord 1988;145:83-95.

58. Peroutka SJ, Sleight AJ, McCarthy BG, et al. The clinical utility of pharmacologic agents that act at serotonin receptors. J Neuropsychiatry 1989;3:253-262.

59. Peroutka S. 5-hydroxytryptamine receptor subtypes: molecular, biochemical, and physiological characterization. Trends Neurosci 1989;11:496-500.

60. Perry P, Browne J, Alexander B, et al. Relationships of free nortriptyline levels to therapeutic response. Acta Psychiatr Scand 1985;72:120-125.

61. Preskorn S, Silkey B, Beber J, et al. Antidepressant response and plasma concentration of fluoxetine. Ann Clin Psychiatry 1991;3:147-151.

62. Preskorn S, Fast G. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991;52:23-33.

63. Preskorn S, Othmer S. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 1984;4:20-34.

64. Preskorn S, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992;53:5-18.

65. Preskorn S, Bupp S, Weller E, et al. Plasma levels of imipramine and metabolites in 68 hospitalized children. J Am Acad Child Adolesc Psychiatry 1989;3:373-375.

66. Preskorn S, Burke M, Fast G. Therapeutic drug monitoring: Principles and practice. Psychiatr Clin N Am 1993;16:611-645.

67. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56(suppl 6):12-21.

68. Preskorn SH, Janicak PG, Davis JM, Ayd FJ, Jr.: Advances in the pharmacotherapy of depressive disorders. In: Janicak PG, ed. Principles and practice of psychopharmacotherapy. Volume 1, No. 2. Baltimore, Maryland: Williams and Wilkins, 1994.

69. Preskorn S. Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. J Clin Psychiatry 1989,50(suppl):34-42.

70. Preskorn S, Irwin H. Toxicity of tricyclic antidepressants: kinetics, mechanism, intervention: a review. J Clin Psychiatry 1982;43:151-156.

71. Preskorn S. Pharmacokinetics of antidepressants: why and how are they relevant to treatment. J Clin Psychiatry 1993;54:14-34.

72. Preskorn S. Should bupropion dose be adjusted based upon therapeutic drug monitoring? Psychopharmacol Bull 1991;27:637-643.

73. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993;94(suppl 5A):2S-12S.

74. Preskorn SH. Clinical pharmacology of the selective serotonin reuptake inhibitors. Caddo, Oklahoma: Professional Communications, Inc. 1996:50-105.

75. Preskorn SH. Selection of an antidepressant: mirtazapine. J Clin Psychiatry 1997;58(Suppl 6):3-8.

76. Quitkin F, Harrison W, Liebowitz M, et al. Defining the boundaries of atypical depression. J Clin Psychiatry 1984;45:19-21.

77. Quitkin F, McGrath P, Stewart J, et al. Chronological milestones to guide drug change: When should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-792.

78. Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors, Part I: a comparative study. J Clin Psychopharmacol 1984;4:270-278.

79. Ravvaris CL, Nies A, Robinson DS, et al. A multiple-dose, controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 1976;33:347-350.

80. Reimherr F, Chouinard G, Cohn C, et al. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51:18-27.

81. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52:4-10.

82. Richelson E. Pharmacology of antidepressants—characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081.

83. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of anxiety disorders. Arch Gen Psychiatry 1993;50:884-895.

84. Roose SP, Glassman AH. Antidepressent choice in the patient with cardiac disease: lessons from the cardiac arrhythmia suppressia trial (CAST) studies. J Clin Psychiatry 1994;55(Suppl.):83-87.

85. Schatzberg A. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991;52:14-20.

86. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991;29:479-484.

87. Sheehan D, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Pharmacol 1983;3:28-31.

88. Shuey DL, Sadler TW, Lauder JM. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 1992;46:367-378.

89. Sousa F, Goodwin G. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991;17:486-493.

90. Stern W, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic resistant or intolerant patients. J Clin Psychiatry 1983;44:148-152.

91. Stewart J, McGrath P, Rabkin J, Quitkin F. Atypical depression: a valid clinical entity? Psych Clin N Am 1993;16:479-495.

92. Stokes P. Fluoxetine: a five year review. Clin Ther 1993;15:216-243.

93. Stokes P. The changing horizon in the treatment of depression: Scientific/clinical publication overview. J Clin Psychiatry 1991;52:35-43.

94. Sussman N. The potential benefits of serotonin receptor-specific agents. J Clin Psychiatry 1994;55:45-51.

95. Taveres MA, Silva MC, Silva-Araujo A, et al. Effects of prenatal exposure to amphetamine in the medial prefrontal cortex of the rat. Int J Dev Neurosci 1996;14:585-596.

96. Thacker S. Meta-analysis: a quantitative approach to research integration. JAMA 1988;259:1685-1689.

97. Thase M, Mallinger A, McKnight D, Himmelhoch J. Treatment of imipramine-resistant recurrent depression. IV: A double blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-198.

98. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after a myocardial infarction. N Eng J Med 1992;327:227-233.

99. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Eng J Med 1989;321:406-412.

100. Vitullo R, Wharton J, Allen N, et al. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest 1990;98:247-248.

101. Wisner K, Perel J, Findling R. Antidepressant treatment during breast feeding. Am J Psychiatry 1996;153:1132-1137.

102. Workman E, Short D. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 1993;54:5-12.

103. Wright G, Galloway L, Kim J, et al. Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects. J Clin Psychiatry 1985;46:22-25.

104. Zamfir O, Brogna P, Baudrie V, et al. Effects of cold stress on some 5HT1a, 5HT1c, and 5HT2 receptor mediated responses. Eur J Pharmacol 1992;219:261-269.

105. Zornberg G, Pope H. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993;13:397-408.

106. Zung W. Review of placebo controlled trials with bupropion. J Clin Psychiatry 1983;44:104-114.

Back to Chapter

published 2000